EGFR and lung adenocarcinoma: In a multicenter retrospective study, researchers found adjuvant EGFT-TKIs might be a beneficial choice compared with EGFR-TKIs plus chemotherapy in EGFR-mutant stage III-pN2 lung adenocarcinoma [29].